Top Alternatives,State-licensed pharmacies must stop making most compounded semaglutide

The question of can I still get compound semaglutide is a complex one, with recent regulatory shifts significantly impacting its availability. While compounded semaglutide was once a more readily accessible option, particularly during periods of national shortage for its FDA-approved counterparts like Ozempic and Wegovy, the landscape has changed. Understanding these changes is crucial for individuals seeking this medication for conditions such as type 2 diabetes and weight management.

The FDA has declared an end to the semaglutide and tirzepatide shortages, a pivotal development that has led to new regulations for compounding pharmacies. This means that many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. Specifically, state-licensed pharmacies must stop making most compounded semaglutide by April 22, 2025, and larger outsourcing facilities by May 22, 2025. Consequently, compounding pharmacies can no longer make and sell semaglutide injections after these dates, unless they meet specific criteria.

It's important to clarify what compounded semaglutide is. Unlike FDA-approved medications manufactured by pharmaceutical companies, compounded semaglutide is a medication that pharmacies create from scratch. This means compounded "semaglutide" is NOT approved by the FDA and has not undergone the rigorous review process for safety, effectiveness, and quality that approved drugs do. While compounded medications are not FDA approved, they can be lawfully marketed if they comply with specific sections of the Federal Food, Drug, and Cosmetic Act. However, the FDA has expressed concerns regarding certain forms of compounded semaglutide, warning that salt forms should not be used to compound semaglutide.

The availability of compounded semaglutide is now more restricted. While it was previously more widely available, the statement that compounded semaglutide products are no longer permitted under current regulations reflects the tightening of rules. In some regions, like Australia, the Therapeutics Goods Administration prohibited pharmacists from compounding GLP-1 RAs, including semaglutide, in 2024. Similarly, the FDA's stance has led to a situation where it is illegal to make or sell compounded semaglutide, with rare exceptions.

For those who previously relied on compounded semaglutide, this shift can be concerning. Some healthcare professionals and telehealth platforms, such as Hims & Hers, have indicated they will keep offering compounded semaglutide to eligible patients despite the upcoming FDA restrictions, suggesting that some avenues may still exist, albeit under stricter conditions. The key is to always get compounded semaglutide from a reputable, licensed pharmacy with a legal prescription.

When considering compounded semaglutide, it's vital to understand that it is not the same as FDA-approved versions like Ozempic. While both may be used for the treatment of type 2 diabetes and weight management, Ozempic is approved by the FDA, but compounded semaglutide is not. The effectiveness and safety profiles can differ significantly. The FDA's focus on ending the shortage means that the emphasis is shifting back towards approved medications.

The "shortage" aspect is also evolving. The semaglutide and tirzepatide shortages are officially over, which has prompted the FDA to restrict the mass compounding semaglutide. This means that the primary justification for widespread compounding – the shortage – is no longer in effect.

For individuals seeking semaglutide, the current situation necessitates careful consideration. While the availability of compounded semaglutide has diminished due to regulatory changes following the resolution of drug shortages, it is still possible to get compounded semaglutide through specific channels, provided a valid prescription is obtained from a healthcare professional who then fills it through a licensed compounding pharmacy. However, the emphasis is increasingly on FDA-approved formulations. The key is to have informed discussions with your healthcare provider about all available options, understanding the risks and benefits associated with both FDA-approved and compounded medications. The volume of compounded semaglutide scripts has been significant, but the regulatory environment is now demanding greater scrutiny and adherence to established pharmaceutical standards for patient safety and drug efficacy.